A treatment regimen for a patient diagnosed with intermediate to high risk prostate cancer. The regimen is a combination therapy that includes (-) fractionated radiation therapy, (-) administration of a therapeutic amount of genistein, and (-) administration of a therapeutic amount of a gonadotropin-releasing hormonal oncologic. The treatment regimen allows the gonadotropin-releasing hormonal oncologic to be administered at a reduced dosing regimen relative to the conventional androgen deprivation therapy dosing regimen for the oncologic with minimal reduction in efficacy, thereby allowing adjustments to the androgen deprivation therapy component of the treatment regimen as necessary and appropriate for alleviating the adverse side effects that accompany androgen deprivation therapy.
